RxDoctor Payments Data

Stephanie Roberts, PA

Medical · Shoshone, IDNPI 1144393257

Payments from drug & device makers

$637in general payments, 2019–2025

Across 34 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$84
  • Exact Sciences$67
  • Corcept Therapeutics$60
  • Cardiva Medical, Inc.$51
  • Abbott$50
  • Novo Nordisk$43
  • plus $282 from 13 others

What the payments were for

  • Food & beverage$58792%
  • Other$508%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$637 in reported general payments places this provider in the 60th percentile of 265 medical providers in Idaho.

See all medical providers in Idaho

Medicare billing

Part B allowed, 2024
$1,452
Medicare patients
48
Services billed
142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide94$103,279
JardianceEmpagliflozin69$56,599
EliquisApixaban41$37,799
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$26,992
Tresiba Flextouch U-200Insulin Degludec22$25,355
Tresiba Flextouch U-100Insulin Degludec36$22,610
TrulicityDulaglutide22$17,548
XareltoRivaroxaban17$14,091
MounjaroTirzepatide13$13,762
Synjardy XrEmpagliflozin/Metformin Hcl16$12,782
Combivent RespimatIpratropium/Albuterol Sulfate15$12,401
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$8,001
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$4,025
Novolog FlexpenInsulin Aspart13$2,756
Xigduo XrDapaglifloz Propaned/Metformin12$2,498

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$43$103,27994 claims
Boehringer IngelheimJardiance, Synjardy Xr, Combivent Respimat$29$81,781100 claims
PfizerEliquis$14$37,79941 claims
Lilly USA, LLCTrulicity, Mounjaro$42$31,31035 claims
GSKTrelegy Ellipta$16$26,99231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 265 medical providers in Idaho.

Other medical in Shoshone

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →